Product Description
Addex Pharma is developing Dipraglurant as a treatment for post-stroke sensorimotor recovery. (Sourced from: https://www.addextherapeutics.com/en/pipeline/researches/dipraglurant-pd-lid/)
Mechanisms of Action: MGLUR5 Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Addex Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Dyskinesias|Parkinson's Disease|Dyskinesia, Drug-Induced
Phase 2: Parkinson's Disease|Dyskinesias|Blepharospasm|Dystonic Disorders|Dystonia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADX48621-302 | P3 |
Unknown status |
Dyskinesia, Drug-Induced|Parkinson's Disease|Dyskinesias |
2023-12-01 |
95% |
| ADX48621-301 | P3 |
Unknown status |
Dyskinesia, Drug-Induced|Parkinson's Disease|Dyskinesias |
2023-08-01 |
95% |
| ADX48621-203 | P2 |
Unknown status |
Dystonic Disorders|Blepharospasm|Dystonia |
2021-12-01 |
32% |
| ADX48621-104 | P1 |
Completed |
Healthy Volunteers |
2017-12-01 |